Curemark announced results from its Phase 3 study of CM-AT for the treatment of autism in children 3 to 8 years of age. The double-blind, randomized, placebo-controlled, multicenter trial met its primary and secondary endpoints, demonstrating a statistically significant effect of CM-AT over placebo on both core and non-core symptoms of autism.
CM-AT has been granted Fast Track status by the FDA with ongoing analysis of the full trial data. CM-AT is being developed under Curemark’s enzyme-replacement therapy for children with autism.
For more information, call (914) 925-3450 or visit www.curemark.com.